Date: 2012-11-19
Type of information: Development agreement
Compound: recombinant Modified Vaccinia virus Ankara (MVA)-based vaccines including MVA-BN®-based human vaccine against the viral hemorrhagic fever Marburg and MVA-BN®-based animal vaccine against Foot-and-mouth disease
Company: Bavarian Nordic (Denmark) U.S. Department of Homeland Security (DHS - USA) Science and Technology Directorate - National Institutes of Health (NIH - USA)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease: viral hemorrhagic fever Marburg, Foot-and-mouth disease
Details: Bavarian Nordic has announced that the U.S. Department of Homeland Security (DHS) Science and Technology Directorate and the National Institutes of Health (NIH) have awarded the company two new contracts valued at up to $18.9 million for the development of recombinant Modified Vaccinia virus Ankara (MVA)-based vaccines, building on the company\'s MVA-BN® platform.
The NIH contract, valued at up to $17.9 million, supports the advanced development of a MVA-BN®-based human vaccine against the viral hemorrhagic fever Marburg, as well as the evaluation of novel technologies to enhance efficacy. The DHS contract, valued at nearly $1 million, supports the development of a MVA-BN®-based animal vaccine against Foot-and-mouth disease.
These new contracts build on a successful partnership between Bavarian Nordic and the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). These agencies have supported the development, manufacture and stockpiling of IMVAMUNE® smallpox vaccine. As part of that partnership, Bavarian Nordic has built and operates an industrial scale manufacturing facility that currently produces and delivers IMVAMUNE® to the Strategic National Stockpile. This flexible manufacturing capability significantly reduces the cost and risk associated with producing recombinant MVA-BN®-based vaccine candidates.
Financial terms: These two new contracts are valued at up to $18.9 million.
Latest news:
